A multicenter randomized, controlled clinical trial aims to test whether a minimally invasive treatment can relieve chronic pelvic pain and improve the quality of life for women with pelvic venous disease.
A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, according to a preclinical study by Weill Cornell Medicine investigators.
The Class of 2025 learned on March 21 where they will be doing their internship and residency training – setting the stage for the next several years of their medical careers and lives.
As Cornell Tech looks toward future development, it aims to go beyond simply reducing its environmental impact. By continuing to innovate and incorporate new sustainable technologies, the New York City campus is a model for how…
Cornell University experts weigh in after Governor Kathy Hochul announced an indefinite delay to congestion tolling in New York City, weeks before the first-in-the-nation system was set to launch.
People with diabetes who were taking GLP-1 receptor agonist drugs had significantly lower rates of hospital readmission, wound reopening and hematoma after surgery, according to new study.
Sakib Jamal ‘19 was recently chosen for the Forbes 30 Under 30 list, in part for his book, The Young VC's Handbook, a tactical guide for newcomers to venture capital.
Cornell Tech today announced that longtime supporter and Cornell alumnus Frederic Rubinstein ’52, LLB ’55 has donated $1 million to the campus’ Public Interest Technology (PiTech) program to support research that helps to…
Weill Cornell Medicine has received a four-year, $1.4 million grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.
